Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Subodh Verma: Tirzepatide Improves Multiple Cardiovascular Risk Pathways
Aug 18, 2026, 19:40

Subodh Verma: Tirzepatide Improves Multiple Cardiovascular Risk Pathways

Subodh Verma, Heart Surgeon-Scientist at Unity Health Toronto, Professor and Canada Research Chair, CV Surgery at Temerty Medicine, shared a post on X about a recent article he and his colleagues co-authored, published in JACC, adding:

“Delighted to share this new JACC analysis from SURMOUNT-1.

Over 72 weeks, we saw improvements across multiple pathways linked to cardiovascular risk – including inflammation, insulin resistance, adiposity and hepatic stress, endothelial dysfunction, and thrombosis.

At the 15-mg dose of Tirzepatide, placebo-adjusted changes included a 55% reduction in hsCRP, 30% reduction in IL-6, 39% reduction in HOMA-IR, 61% reduction in leptin, and 44% reduction in PAI-1, with adiponectin increasing by 48%.”

Title: Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis

Authors: Naveed Sattar, Bruno Linetzky, Giacomo Ruotolo, Subodh Verma, Harald Sourij, Hui Wang, Kadie Vanderman, Jonathan M. Wilson, Ryan M. Griffin, Adam Stefanski, Paul M. Ridker

Subodh Verma

Stay updated on all scientific advnaces with Hemostasis Today.